The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Plateletpheresis


High impact information on Plateletpheresis

  • Therapeutic recommendations include plateletpheresis for major thrombo-hemorrhagic phenomena, or megakaryocyte suppression with radioactive phosphorus, alkylating agents (such as melphalan), or hydroxyurea; minor symptoms may respond to platelet antiaggregating agents [4].
  • Treatment with thrombocytapheresis and azathioprine or busulfan resulted in reduction of the elevated platelet and white cell counts and was associated with partial correction of the vWF abnormalities and remission of the hemostatic abnormalities [5].
  • Eleven patients with early PD underwent three sequential plateletphereses: while on no medication, after receiving carbidopa/levodopa for 1 month, and after receiving carbidopa/levodopa plus selegiline for 1 additional month [6].
  • In cultures of unprocessed cells derived from plateletpheresis residues or buffy coats, TPA treatment alone induced high levels of IFN and costimulation with TPA and phytohemagglutinin produced some further enhancement of IFN production [7].
  • CONCLUSION: Only a slight and rapidly reversible increase in soluble PDGF-AB was found during plateletpheresis and no increase in soluble TGF-beta1 and beta-TG was found [8].

Biological context of Plateletpheresis


Anatomical context of Plateletpheresis

  • The effects of plateletpheresis on plasma levels of prothrombin fragment (F(1+2)), D-dimer, plasmin-plasmin inhibitor (PPI) complexes, and plasminogen activator inhibitor (PAI-1); on the activation of neutrophils (% L-selectin+); and on the frequency of platelet-neutrophil aggregates (% CD41+ neutrophils) were compared [11].
  • Eight blood donors underwent paired plateletpheresis using the CS 3000 Plus blood cell separator [12].
  • A transient increase in TSA was found in plasmas collected at the end of plateletpheresis during abstinence, but this activity was not detected 12 hr later [13].
  • Relatively large amounts of 22K were produced in leukocyte suspensions isolated from buffy coats after induction with concanavalin A (ConA); induction of plateletpheresis residues with staphylococcal enterotoxin A (SEA) resulted in the production of almost only IFN-gamma (45K) [14].

Associations of Plateletpheresis with chemical compounds


Gene context of Plateletpheresis

  • Interleukin-2 (IL-2), purified to apparent homogeneity, enhanced interferon (IFN) production in phytohemagglutin (PHA)-stimulated cultures of Ficoll-Hypaque-purified human mononuclear cells derived from plateletpheresis residues [18].
  • Over the next 7 days, four unirradiated HLA-matched plateletpheresis units were transfused; one was probably homozygous for both HLA-A and -B antigens (A2, -; B44, -) and was transfused first, and three were probably homozygous for an HLA-B antigen (A2, 29; B44, -) and were white cell reduced [19].
  • RESULTS: Over the course of plateletpheresis, there was a significant increase in mean channel fluorescence intensity (MCFI) of CD62p, from 25.1 +/- 7.9 (mean +/- SD) to 50.4 +/- 28.9, and of CD63, from 22.3 +/- 6.5 to 33.3 +/- 13 [20].
  • We found a significant increase in median plasma level of TNF-alpha following plateletpheresis (3.5 vs 26.5 pg/ml, P=0.02) [21].
  • Single automated donor plateletpheresis increases the plasma level of proinflammatory cytokine tumor necrosis factor-alpha which does not associate with endothelial release markers von Willebrand factor and fibronectin [21].

Analytical, diagnostic and therapeutic context of Plateletpheresis


  1. Reversible acute sensorineural hearing loss associated with essential thrombocytosis. Grisell, D.L., Mills, G.M. Arch. Intern. Med. (1986) [Pubmed]
  2. Relationship of physical symptoms, ECG, free calcium, and other blood chemistries in reinfusion with citrated blood. Ladenson, J.H., Miller, W.V., Sherman, L.A. Transfusion (1978) [Pubmed]
  3. National audit of citrate toxicity in plateletpheresis donors. Makar, Y.F., Butler, M.O., Cockersole, G.M., Gabra, G., Serevitch, J.M. Transfusion medicine (Oxford, England) (2002) [Pubmed]
  4. Neurologic manifestations of essential thrombocythemia. Jabaily, J., Iland, H.J., Laszlo, J., Massey, E.W., Faguet, G.B., Brière, J., Landaw, S.A., Pisciotta, A.V. Ann. Intern. Med. (1983) [Pubmed]
  5. Acquired von Willebrand's disease in the myeloproliferative syndrome. Budde, U., Schaefer, G., Mueller, N., Egli, H., Dent, J., Ruggeri, Z., Zimmerman, T. Blood (1984) [Pubmed]
  6. Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early parkinsonism. Shults, C.W., Nasirian, F., Ward, D.M., Nakano, K., Pay, M., Hill, L.R., Haas, R.H. Neurology (1995) [Pubmed]
  7. Stimulation of human gamma interferon production by diterpene esters. Yip, Y.K., Pang, R.H., Oppenheim, J.D., Nachbar, M.S., Henriksen, D., Zerebeckyj-Eckhardt, I., Vilcek, J. Infect. Immun. (1981) [Pubmed]
  8. Plateletpheresis does not cause long-standing platelet-derived growth factor release into the donor blood. Zimmermann, R., Loew, D., Weisbach, V., Strasser, E., Ringwald, J., Zingsem, J., Eckstein, R. Transfusion (2005) [Pubmed]
  9. Effects of nitric oxide on platelet activation during plateletpheresis and in vivo tracking of biotinylated platelets in humans. Stohlawetz, P., Horvath, M., Pernerstorfer, T., Nguyen, H., Vondrovec, B., Robisch, A., Eichler, H.G., Spitzauer, S., Jilma, B. Transfusion (1999) [Pubmed]
  10. Four pregnancies in two patients with essential thrombocythaemia--a case report. Koh, L.P., Devendra, K., Tien, S.L. Ann. Acad. Med. Singap. (2002) [Pubmed]
  11. Safety issues of plateletpheresis: comparison of the effects of two cell separators on the activation of coagulation, fibrinolysis, and neutrophils and on the formation of neutrophil-platelet aggregates. Stohlawetz, P., Kapiotis, S., Seidl, D., Hergovich, N., Zellner, M., Eichler, H.G., Stiegler, G., Leitner, G., Höcker, P., Jilma, B. Transfusion (1999) [Pubmed]
  12. Paired plateletpheresis with the CS 3000 plus blood cell separator using the new 30 ml low-volume collection chamber and the A-35 collection chamber. Moog, R., Müller, N. Vox Sang. (1993) [Pubmed]
  13. Humoral regulation of thrombopoiesis in man. Adams, W.H., Liu, Y.K., Sullivan, L.W. J. Lab. Clin. Med. (1978) [Pubmed]
  14. Factors influencing the production of human immune interferon components. Van Damme, J., De Ley, M., Muylle, L., Billiau, A. Dev. Biol. Stand. (1983) [Pubmed]
  15. Citrate anticoagulants for plateletpheresis. Huestis, D.W., Fletcher, J.L., White, R.F., Price, M.J. Transfusion (1977) [Pubmed]
  16. Donor exposure to the plasticizer di(2-ethylhexyl)phthalate during plateletpheresis. Buchta, C., Bittner, C., Höcker, P., Macher, M., Schmid, R., Seger, C., Dettke, M. Transfusion (2003) [Pubmed]
  17. Platelet activation during plasma-reduced multicomponent PLT collection: a comparison between COBE Trima and Spectra LRS turbo cell separators. Perseghin, P., Mascaretti, L., Speranza, T., Belotti, D., Baldini, V., Dassi, M., Riva, M., Pogliani, E.M., Sciorelli, G. Transfusion (2004) [Pubmed]
  18. Purified human interleukin-2 enhances induction of immune interferon. Pearlstein, K.T., Palladino, M.A., Welte, K., Vilcek, J. Cell. Immunol. (1983) [Pubmed]
  19. Fatal graft-versus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets from unrelated donors. Benson, K., Marks, A.R., Marshall, M.J., Goldstein, J.D. Transfusion (1994) [Pubmed]
  20. Flow cytometric analysis of platelet membrane antigens during and after continuous-flow plateletpheresis. Gutensohn, K., Bartsch, N., Kuehnl, P. Transfusion (1997) [Pubmed]
  21. Single automated donor plateletpheresis increases the plasma level of proinflammatory cytokine tumor necrosis factor-alpha which does not associate with endothelial release markers von Willebrand factor and fibronectin. Karadoğan, I., Ozdoğan, M., Undar, L. Transfusion science. (2000) [Pubmed]
  22. In vitro and in vivo comparison of single-donor platelets and multiple-donor pooled platelets transfusions in leukemic patients. Patel, I.P., Ambinder, E., Holland, J.F., Aledort, L.M. Transfusion (1978) [Pubmed]
  23. Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation. Bolan, C.D., Cecco, S.A., Wesley, R.A., Horne, M., Yau, Y.Y., Remaley, A.T., Childs, R.W., Barrett, A.J., Rehak, N.N., Leitman, S.F. Transfusion (2002) [Pubmed]
  24. Importance of ionized magnesium measurement for monitoring of citrate-anticoagulated plateletpheresis. Mercan, D., Bastin, G., Lambermont, M., Dupont, E. Transfusion (1997) [Pubmed]
  25. Periodic alternating interface positioning to lower WBC contamination of apheresis platelet concentrates: a multicenter evaluation. Zeiler, T., Zingsem, J., Moog, R., Kretschmer, V., Eckstein, R., Müller, N., Eisenbeisz, F. Transfusion (2000) [Pubmed]
WikiGenes - Universities